首页|期刊导航|中药新药与临床药理|通阳宽胸方配方颗粒与传统汤剂治疗冠心病稳定型心绞痛的疗效及对糖脂代谢与内皮损伤指标的作用比较

通阳宽胸方配方颗粒与传统汤剂治疗冠心病稳定型心绞痛的疗效及对糖脂代谢与内皮损伤指标的作用比较OA

Comparison of the Efficacy of Tongyang Kuanxiongfang Formula Dispensing Granules versus Traditional Decoction in Treating Stable Angina Pectoris of Coronary Heart Disease and Their Effects on Glucose-Lipid Metabolism and Endothelial Injury Markers

中文摘要英文摘要

目的 比较通阳宽胸方配方颗粒与传统饮片汤剂治疗冠心病稳定型心绞痛(气滞痰瘀证)的临床疗效及对糖脂代谢与内皮损伤指标的影响.方法 采用随机、单盲、安慰剂对照临床试验方法,选取 2024 年 5 月至2025 年 5 月广东省第二中医院门诊及住院部符合诊断要求的稳定型心绞痛患者 76 例,按随机数字表法分为试验组与对照组各 38 例.试验组在原西药治疗方案基础上给予通阳宽胸方配方颗粒及中药饮片水煎液安慰剂治疗,对照组在原西药治疗方案基础上给予通阳宽胸方中药饮片水煎液及配方颗粒安慰剂治疗.治疗 4 周后比较两组中医证候疗效、中医证候积分、西雅图心绞痛量表(SAQ)评分、平均每周心绞痛发作次数、平均每次心绞痛持续时间、血清糖脂代谢指标[低密度脂蛋白胆固醇(LDL-C)、氧化型低密度脂蛋白(ox-LDL)、晚期糖基化终末产物(AGEs)、可溶性晚期糖基化终末产物受体(sRAGE)]、血清内皮损伤指标[血管内皮生长因子(VEGF)、血管细胞黏附分子 1(VCAM-1)、细胞间黏附分子 1(ICAM-1)]的变化.结果 治疗后,两组中医证候疗效总有效率均为 92.1%(35/38),两组总有效率差异为 0(95%CI:-0.12~0.12),95%CI的置信下限>-0.18,非劣效性检验成立.治疗后两组患者的中医证候积分明显降低(P<0.05),各项SAQ评分明显升高(P<0.05),平均每周心绞痛发作次数明显减少(P<0.05),平均每次心绞痛持续时间明显缩短(P<0.05),血清LDL-C、ox-LDL、AGEs、VCAM-1、ICAM-1 的水平均明显下降(P<0.05),血清sRAGE、VEGF水平明显升高(P<0.05),且两组间上述指标水平的差异均无统计学意义(P>0.05).结论 通阳宽胸方配方颗粒与通阳宽胸方汤剂治疗稳定型心绞痛(气滞痰瘀证)均有较好的临床疗效,两者在减轻患者心绞痛症状、调节糖脂代谢,改善内皮功能方面的疗效无明显差异.

Objective To compare the clinical efficacy of Tongyang Kuanxiongfang Formula dispensing granules versus its traditional decoction in the treatment of stable angina pectoris of coronary heart disease(with qi stagnation and phlegm stasis syndrome)and their effects on glucose-lipid metabolism and endothelial injury markers.Methods A randomized,single-blind,placebo-controlled clinical trial was conducted.A total of 76 patients with stable angina pectoris who met the diagnostic criteria and were treated at the outpatient or inpatient departments of Guangdong Second Traditional Chinese Medicine Hospital from May 2024 to May 2025 were enrolled.They were divided into a trial group and a control group using a random number table,with 38 cases in each group.On the basis of original western medical treatment,the trial group received Tongyang Kuanxiongfang Formula dispensing granules plus a placebo of traditional herbal decoction,while the control group received the traditional Tongyang Kuanxiongfang Formula decoction plus a placebo of dispensing granules.After 4 weeks of treatment,the two groups were compared in terms of traditional Chinese medicine(TCM)syndrome efficacy,TCM syndrome score,Seattle Angina Questionnaire(SAQ)score,average weekly frequency of angina attacks,average duration of each angina attack,serum glucose-lipid metabolism markers[low-density lipoprotein cholesterol(LDL-C),oxidized low-density lipoprotein(ox-LDL),advanced glycation end products(AGEs),soluble receptor for advanced glycation end products(sRAGE)],and serum endothelial injury markers[vascular endothelial growth factor(VEGF),vascular cell adhesion molecule-1(VCAM-1),intercellular adhesion molecule-1(ICAM-1)].Results After treatment,the total response rate for TCM syndrome efficacy was 92.1%(35/38)in both groups,with a difference in total response rates of 0(95%CI:-0.12 to 0.12).The lower limit of the 95%CI was>-0.18,establishing non-inferiority.After treatment,TCM syndrome scores were significantly decreased in both groups(P<0.05);SAQ scores were significantly increased in both groups(P<0.05);the average weekly frequency of angina attacks were significantly decreased(P<0.05);the average duration of each angina attack was significantly shortened(P<0.05);serum levels of LDL-C,ox-LDL,AGEs,VCAM-1,and ICAM-1 were significantly decreased in both groups(P<0.05);and serum levels of sRAGE and VEGF were significantly increased in both groups(P<0.05).There were no statistically significant differences in the above-mentioned indicators between the two groups(P>0.05).Conclusion Both Tongyang Kuanxiongfang Formula dispensing granules and the traditional Tongyang Kuanxiongfang Formula decoction demonstrate favorable clinical efficacy in treating stable angina pectoris of coronary heart disease(with qi stagnation and phlegm stasis syndrome),with no significant differences between the two formulations in alleviating angina symptoms,regulating glucose-lipid metabolism,or improving endothelial function.

陈慧龙;廖芸楚;徐嘉辉;漆娜;梁文坚

广州中医药大学第五临床医学院,广东 广州 510405广州中医药大学第五临床医学院,广东 广州 510405广东省第二中医院,广东 广州 510095广东省第二中医院,广东 广州 510095广东省第二中医院,广东 广州 510095

医药卫生

通阳宽胸方传统饮片汤剂中药配方颗粒冠心病稳定型心绞痛气滞痰瘀证糖脂代谢内皮损伤疗效比较

Tongyang Kuanxiongfang Formulatraditional herbal decoctionChinese medicinal dispensing granulescoronary heart diseasestable angina pectorisqi stagnation and phlegm stasis syndromeglucose-lipid metabolismendothelial injuryefficacy comparison

《中药新药与临床药理》 2026 (6)

1146-1154,9

广东省基础与应用基础研究基金项目(2022A1515220151)广东省中医药局科研项目(20241015)广州中医药大学校院联合科技创新基金项目(GZYSE2024C03,GZYSE2024Y09).

10.19378/j.issn.1003-9783.2026.06.016

评论